Huadong Medicine products gain inclusion in national drug directories

On December 7, 2025, Huadong Medicine Co., Ltd. announced that its products and cooperative products were included in the new version of the National Medical Insurance Drug Catalog and the Commercial Health Insurance Innovative Drug Catalog, effective January 1, 2026. This inclusion is expected to support product market promotion.

Key inclusions are: Cenapali capsules and Linagliptin tablets, which are now part of the negotiated drug section within the medical insurance catalog, with an agreement valid until January 2027. Additionally, Zavokiosolone injection was added to the commercial innovative drug catalog, also with an agreement until December 2027.

Furthermore, ustekinumab injection, a product of Huadong Medicine's wholly-owned subsidiary Hangzhou Sino-America Huadong Pharmaceutical Co., Ltd., has been reclassified under routine catalog management. The payment scope for this product has been adjusted from the previous version of the drug catalog. The company stated that these inclusions are not expected to significantly impact its recent performance but will aid future market expansion.